Target RWE at #TLM2024
Learn about our activity at The Liver Meeting & our real-world evidence solutions
Join Us and Explore Our Latest Research
Target RWE is excited to attend and sponsor AASLD's 2024 The Liver Meeting event in San Diego, November 15-19. We will present new data on Metabolic Dysfunction–Associated Steatohepatitis (MASH) topics including racial and ethnic disparities, patient characteristics, disease progression, patient-reported outcomes, and GLP-1 receptor agonists. Additionally, we will share new primary biliary cholangitis (PBC) data related to complication-free survival. Target RWE looks forward to connecting with the liver disease community and continuing our contribution to the ongoing advancements in patient care!
Proven Leadership in Liver Disease
“I’m thrilled to be attending The Liver Meeting this year in San Diego. It’s been incredible to witness the growth and progress of AASLD both during and after my presidency. Since my first attendance, I’ve been inspired by the dedication and innovation displayed each year at The Liver Meeting. I look forward to seeing the latest advancements in research and patient care in the field of Hepatology.” Michael W. Fried, MD, FAASLD Co-Founder, Chief Medical Officer & Former AASLD President
Notable Accomplishments:
- Founder and Co-principal investigator of the HCV-TARGET network – The highly successful collaborative framework for real world evidence generation
- Awarded the FDA Excellence in Regulatory Science Award for contributions to optimizing management for Hepatitis C
- Principal investigator of several NIH cooperative clinical trials
Strategic Partnership with AASLD
Target RWE's proud to collaborate with the American Association for the Study of Liver Diseases (AASLD) and have worked to successfully enroll over 75,000 patients in the TARGET-Liver Disease (LD) registry.
Our partnership facilitates the study of the natural history of disease and the evaluation of patient characteristics, disease management, treatments, and clinical outcomes among many subpopulations of patients with chronic liver disease, including MASLD, HBV, MASH, HCC, PBC, and PSC. The extensive data set supports AASLD's CQC initiative of a Learning Health Network to improve the quality, safety, and value of care for patients living with chronic liver disease and cirrhosis.
Event Details & Target RWE Booth Location
Location: San Diego Convention Center
Address: 111 W Harbor Dr, San Diego, CA 92101
Dates: November 15-19, 2024
Booth Location: Target RWE booth #1650
Exhibit Hall Hours: Sunday, November 17th & Monday, November 18th from 9:30 AM – 4:30 PM
Target RWE Presentations at The Liver Meeting
Abstract Presentation #203 (Nov. 17th, 8:15am-8:30am)
Use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality
Abstract Poster #2357 (Nov. 16th, 8:00am-5:00pm)
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in a Real- World US Cohort
Abstract Poster #4313 (Nov. 18th, 8:00am-5:00pm)
Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep versus Adequate ALP Response to UDCA
Abstract Poster #2305 (Nov. 16th, 8:00am-5:00pm)
Understanding Metabolic Dysfunction–Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups
Abstract Poster #2356 (Nov. 16th, 8:00am-5:00pm)
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Abstract Poster (Nov. 16th 8:00am-5:00pm)
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status
Abstract Poster #2341 (Nov. 16th, 8:00am-5:00pm)
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Recent Presentations Progressing MASH Research
Real World Use of Glucagon Like Peptide Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis form TARGET-NASH
Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study analysis at EASL 2024 titled “Real-World Use of Glucagon Like Peptide 1 Receptor Agonist in Patients with MASLD: A Cross-Sectional Analysis from Target NASH.”
The study analyzed the use of GLP-1 receptor agonists in real world patients diagnosed with MASL, metabolic dysfunction-associated steatohepatitis (MASH), and MASLD with cirrhosis – finding that 11% of the adult cohort were prescribe GLP-1 therapy.
A Prospective Assessment of Disease Progression Impact on Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at EASL 2024 titled “A Prospective Assessment of Disease Progression Impact on Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.”
Focusing on metabolic dysfunction-associated stereotactic liver disease (MASLD), the study investigated disease progression impact on patient-reported outcomes (PROs) and highlights the increased burden on patients as the disease advances.
TARGET-LD: A Comprehensive Registry for Liver Disease Research in the Real World
TARGET-LD is the world's largest liver disease registry, encompassing over 600,000 patients and capturing a diverse range of patient profiles. With its extensive patient population, diverse data collection, and strong partnerships, including AASLD, TARGET-LD is a valuable resource for researchers seeking to advance their understanding of liver diseases and develop innovative treatments.
Schedule a Meeting with Our Team
Julie Rockey, MBA, RHIA
Vice President, Business Development & Strategic Partnerships
